Give to GCHS

- Our Expertise Overview
- Why Nebraska?
  Nebraska’s difference is an all-star, all-volunteer team that dedicated itself to being ready for any biocontainment crisis at any time.
- Leadership
  The Global Center is led by experts in biopreparedness and high-consequence infections research, education and clinical care.
- Scholars
  Our scholars are leading advancements in global health security.
- Affiliates
  Our affiliates are innovative experts collaborating to advance global health security.
- C-STARS
  C-STARS, the Center for Sustainment of Trauma Readiness Skills- Omaha is a collaboration between UNMC, Nebraska Medicine, and the Air Force Research Laboratory’s School of Aerospace Medicine. C-STARS Omaha works closely with UNMC’s Global Center for Health Security, iEXCEL, and the Nebraska Biocontainment Unit to take advantage of the medical center’s capabilities and expertise in biopreparedness training and research.
- Our Team
  Our team consists of a variety of professionals providing support and project management to further the Global Center for Health Security’s mission.
- Domains Overview
- Clinical Operations
  The Global Center for Health Security is the premier U.S. institution for management of high-consequence infections. Further, our clinical capabilities include biological, chemical, burn, and radiation domains.
- Education & Training
  Our expertise is now sought worldwide and officially sanctioned by the U.S. government. The GCHS is the home base to the national Training, Simulation, and Quarantine Center and the Nebraska Biocontainment Unit.
- Research
  The GCHS has laser-focused existing work by our leading scientists in fields like chemical weapons, drug discovery and public health.
- International Partnerships & Innovation
  The GCHS tackles the most pressing problems in emerging infectious diseases through international partnerships and innovation.
- Programs Overview
- Core Capabilities
  Learn about the GCHS’ 4 core capabilities: Emerging Pathogens Lab , Nebraska Biocontainment Unit , the National Quarantine Unit, and deployable teams.
- Core Programs
  The GCHS works with multiple core programs to enhance our capabilities to respond effectively to public health challenges.
- Partnerships
  The GCHS partners with many outside organizations to strengthen our commitment to addressing global health challenges through research and innovation.
- Associated Groups & Programs
  Learn more about the impactful programs led by GCHS leadership, scholar, and affiliates.
- Academic Programs
  Explore GCHS academic programs which include the Health Security Fellowship and the Biological Defense and Health Security program.
- Health Emergencies Overview
- Outbreaks to Watch
  Find information about emerging pathogens, diseases and outbreaks from around the world. Stay updated on the most recent information on worldwide global health and emerging pathogens outbreaks.
- COVID-19
  Explore our COVID-19 page for recent news, resources, manuals, and playbooks. Biweekly overviews of new data and developments presented by James V. Lawler, MD, MPH, FIDSA can now be found on the Health Emergencies page.
- HPAI H5N1- Avian Influenza
  Learn more about the current worldwide outbreak of HPAI H5N1- Avian Influenza and explore resources, news, webinars, and our unofficial map.
- Marburg Virus Disease
  Explore this page for comprehensive resources, information, news, and situational updates on the ongoing Marburg Virus Disease outbreak.
- Mpox
  The Global Center for Health Security is currently monitoring the spread of mpox. Learn more by viewing our resources.
- Measles
  The GCHS is currently monitoring measles cases. This page provides information, resources, and news.
The Transmission
- News Overview
- Events
  Find scheduled and past events involving the Global Center for Health Security.
- Annual Reports
  Find annual reports for our center and several of our programs.

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Published Apr 24, 2024

CureVac

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat
Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone
Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Leave a comment Cancel reply